Virtus LifeSci Biotech Products ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Virtus LifeSci Biotech Products ETF BBP
Morningstar’s Analysis BBP
Will BBP outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the BBP management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of BBP’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 27.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
ImmunityBio Inc Ordinary Shares | 4.96 | 4M | Healthcare |
Iovance Biotherapeutics Inc | 3.20 | 2M | Healthcare |
Moderna Inc | 2.81 | 2M | Healthcare |
KalVista Pharmaceuticals Inc | 2.56 | 2M | Healthcare |
Axsome Therapeutics Inc | 2.51 | 2M | Healthcare |
Novavax Inc | 2.49 | 2M | Healthcare |
Legend Biotech Corp ADR | 2.46 | 2M | Healthcare |
Mirum Pharmaceuticals Inc | 2.28 | 2M | Healthcare |
Roivant Sciences Ltd Ordinary Shares | 2.14 | 2M | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 2.13 | 2M | Healthcare |
United States